Le Foll Bernard, Di Ciano Patricia
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON, Canada M5S 2S1; Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M6J 1H4; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON, Canada M5S 2S1; Department of Family and Community Medicine, University of Toronto, Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto, Canada; Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, Canada; Institute of Medical Sciences, University of Toronto, Toronto, Canada.
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON, Canada M5S 2S1.
Eur Neuropsychopharmacol. 2015 Sep;25(9):1401-9. doi: 10.1016/j.euroneuro.2014.08.017. Epub 2014 Sep 16.
Since the cloning of the D3 receptor in the early 1990s, there has been a great deal of interest in this receptor as a possible therapeutic target for drug addiction. The development of a D3 ligand suitable for use in humans has remained elusive, so the study of the function of the D3 receptor and its possible therapeutic efficacy has largely been restricted to animals. Pre-clinical studies have established that systemic administration of D3 ligands, particularly antagonists and partial agonists, can alter drug-seeking in animals. Despite over a decade of research, few studies have investigated the effects of intra-cerebral infusion of D3 ligands on drug-seeking. In the present review, these studies are summarized, which have largely focused on stimulus-controlled behaviors. Converging evidence from studies of D3 receptor expression, Fos and pharmacological Magnetic Resonance Imaging (phMRI) is also provided to delineate some of the D3 brain systems involved in drug-seeking and taking. The data so far indicate that different brain systems may be involved in different types of stimulus control as well as drug taking.
自20世纪90年代初克隆出D3受体以来,人们对该受体作为药物成瘾潜在治疗靶点产生了浓厚兴趣。开发适用于人类的D3配体一直难以实现,因此对D3受体功能及其可能的治疗效果的研究在很大程度上局限于动物。临床前研究已证实,全身性给予D3配体,尤其是拮抗剂和部分激动剂,可改变动物的觅药行为。尽管经过了十多年的研究,但很少有研究调查脑内注入D3配体对觅药行为的影响。在本综述中,总结了这些主要关注刺激控制行为的研究。还提供了来自D3受体表达、Fos和药理学磁共振成像(phMRI)研究的汇聚证据,以描绘一些参与觅药和用药行为的D3脑系统。目前的数据表明,不同的脑系统可能参与不同类型的刺激控制以及药物摄取。